Mpathix Inc.
Mpathix Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Mpathix Inc..
Mpathix Inc. is a company.
Key people at Mpathix Inc..
Key people at Mpathix Inc..
mPathix Health, Inc. (often referred to as mPathix Inc.) is a clinical-stage medical device company focused on developing, producing, and distributing multi-modal pain management and central nervous system (CNS) related solutions.[1][2][3] It operates as a wholly owned subsidiary of Qualis Innovations Inc. (OTC: QLIS) following a reverse merger in June 2021, where mPathix acquired Qualis, with its lead product being the SOLACE electromagnetic induction device cleared by the FDA for pain relief, muscle spasms, and joint contractures (but not malignancies).[3][5] The company serves patients and clinicians facing unmet needs in pain management through innovative, modality-agnostic products via a virtual operating model, positioning it in the growing non-opioid pain therapy market.[3]
mPathix Health, Inc. emerged from EMF Medical Devices, Inc., rebranding to mPathix in May 2021 amid strategic shifts.[1][4] It completed a reverse merger with Qualis Innovations Inc. on June 29, 2021, allowing mPathix to go public via the OTC market (QLIS).[5] Key leadership includes CEO Demir Bingol, who highlighted growth initiatives, and appointees like Sr. Vice President James “Skip” Thurman in August 2021, bringing Fortune 200 healthcare communications expertise from DaVita.[3] Early pivots centered on clinical-stage development of devices like SOLACE, building on FDA clearances for pain-related conditions.[3]
(Note: Specific founder backgrounds pre-merger are not detailed in available sources; the focus post-2021 is on corporate evolution through acquisition and executive hires.[3][4][5])
mPathix rides the trend toward non-opioid, non-invasive pain management amid the global push to address the opioid crisis and CNS disorders, where market forces favor FDA-cleared devices over pharmaceuticals.[3] Timing aligns with post-2021 healthcare innovation waves, leveraging virtual models for scalable development in a sector projected for growth due to aging populations and chronic pain prevalence. It influences the medtech ecosystem by advancing multi-modal solutions, potentially reducing reliance on traditional therapies and enabling clinician adoption through targeted clearances.[1][3]
mPathix is poised for expansion via funding (e.g., CIM Securities agreement) and leadership hires, focusing on SOLACE commercialization and new CNS products.[2][3] Trends like AI-enhanced medtech and regulatory tailwinds for non-opioids will shape its path, potentially amplifying influence through partnerships or further public market milestones. As a clinical-stage player post-merger, its trajectory hinges on trial successes and distribution scaling, tying back to its core mission of unmet pain needs in a high-demand landscape.[1][2][3]
